01 Growing Approvals for Monoclonal AntibodiesThe growing number of FDA approvals for monoclonal antibodies is anticipated to provide a profitable opportunity for market expansion during the projected timeframe. In May 2023, the FDA approved EPKINLYTM for treating diffuse large B-cell lymphoma in adult patients. In 2023, the FDA approved 55 new molecular entities (NMEs). These included 38 small-molecule drugs, which encompass peptide- and oligonucleotide-based molecules, as well as five non-antibody biologics and 12 antibody-based biologics (i.e., biologics containing one or more antibody domains).Additionally, the increasing prevalence of both communicable and non-communicable diseases necessitates regulatory agencies such as the FDA to expedite the approval process for monoclonal antibodies, which can be utilized for research and development. Therefore, the increasing acceptance of monoclonal antibodies is expected to drive the market's growth.
02 Increasing InvestmentThe market expansion is anticipated to be driven by a rise in investment towards research and development of monoclonal antibodies, particularly in cancer treatment, which constitutes about 50% of all research and development programs associated with monoclonal antibodies. The focused strategy of monoclonal antibodies (mAbs) has transformed the field of cancer therapy by minimizing adverse reactions and enhancing patient results. However, continuous research and development are essential to strengthen the effectiveness of monoclonal antibodies (mAb) in cancer treatment.
01 Complexity and High Cost of ProductionIsolating antibodies from intricate mixtures might present difficulties and consume a significant amount of time. The necessity for high levels of purity and the removal of contaminants might result in labor-intensive and expensive procedures. Moreover, the generation of antibodies, particularly for therapeutic applications, can incur high costs due to the requirement for specialized apparatus, cell culture conditions, and purification techniques.Despite the potential of mAb treatments in treating various diseases, their availability to a broader group of patients still needs to be expanded due to several obstacles. A significant obstacle is that the existing techniques for producing large quantities of clinical-grade monoclonal antibodies (mAbs) are laborious and expensive. Due to their vast size, chemical synthesis methods are not feasible for producing monoclonal antibodies (mAbs). Lower organism expression platforms are unsuited for commercial mAb production since they cannot provide the necessary glycosylation and folding.Moreover, the expenses linked to the production of a significant quantity of antibody-based medicines can affect the availability of these treatments. Therefore, this is anticipated to significantly impede the market's expansion during the projected timeframe.
01 Rise in Chronic DiseaseThe market growth is predicted to be driven by the increasing prevalence of chronic diseases and the growing aging population. According to PAHO, it is anticipated that there will be 20 million new cases of cancer worldwide. Over the next two decades, the incidence of cancer is projected to increase by almost 60%, which will impose further pressure on healthcare systems, individuals, and communities. It is projected that by 2040, the global incidence of cancer will increase by around 30 million cases.In addition to its consequences, chronic illness exerts a significant influence on the healthcare system of the United States. Approximately 90% of the yearly USD 4.1 trillion healthcare expenditure is allocated to the management and treatment of chronic diseases and mental health disorders. The increasing prevalence of diseases would compel the industry to enhance its production capacity and research efforts for innovation and progress. Hence, the facts above contribute to the expansion of the market over the projected timeframe.
May 2026 Thermo Fisher Scientific expanded its biologics manufacturing portfolio with advanced antibody production technologies designed to improve process scalability, yield, and manufacturing efficiency.
February 2026 Cytiva introduced next-generation upstream bioprocessing solutions to enhance monoclonal antibody production through improved cell culture performance and process automation.
October 2025 Sartorius expanded its single-use bioprocessing portfolio with new technologies to optimize antibody production, purification, and commercial-scale manufacturing.
June 2025 Merck KGaA introduced advanced cell culture media and bioprocessing solutions designed to improve productivity and consistency in monoclonal antibody manufacturing.